{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:39:28Z","timestamp":1792445968655,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"DOI":"10.1245\/s10434-026-20378-w","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:50:06Z","timestamp":1792443006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Adoption of Adjuvant Immune Checkpoint Inhibition in Stage IIB\/IIC Melanoma Following FDA Approval"],"prefix":"10.1245","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8005-1072","authenticated-orcid":false,"given":"James W.","family":"Jakub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bently P.","family":"Doonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney N.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz Z.","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Seetharam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pockaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Yahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana S.","family":"Dronca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"20378_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin."},{"key":"20378_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold M, Singh D, Laversanne M, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158:495\u2013503.","journal-title":"JAMA Dermatol."},{"key":"20378_CR3","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1001\/jama.2025.13074","volume":"334","author":"UM Joshi","year":"2025","unstructured":"Joshi UM, Kashani-Sabet M, Kirkwood JM. Cutaneous melanoma: a review. JAMA. 2025;334:2113\u201325.","journal-title":"JAMA."},{"key":"20378_CR4","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67: 472\u201392.","DOI":"10.3322\/caac.21409"},{"key":"20378_CR5","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399:1718\u201329.","journal-title":"Lancet."},{"key":"20378_CR6","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","volume":"29","author":"JM Kirkwood","year":"2023","unstructured":"Kirkwood JM, Del Vecchio M, Weber J, et al. Adjuvant nivolumab in resected stage IIB\/C melanoma: Primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023;29:2835\u201343.","journal-title":"Nat Med."},{"key":"20378_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 1.2026. NCCN.org. Accessed March 28, 2026."},{"key":"20378_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115381","volume":"220","author":"JJ Luke","year":"2025","unstructured":"Luke JJ, Ascierto PA, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025;220:115381.","journal-title":"Eur J Cancer."},{"key":"20378_CR9","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1245\/s10434-024-15393-8","volume":"31","author":"BE Palis","year":"2024","unstructured":"Palis BE, Janczewski LM, Browner AE, et al. The National Cancer Database conforms to the standardized framework for registry and data quality. Ann Surg Oncol. 2024;31:5546\u201359.","journal-title":"Ann Surg Oncol."},{"key":"20378_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMoa2504966","volume":"394","author":"PA Ascierto","year":"2026","unstructured":"Ascierto PA, Del Vecchio M, Merelli B, et al. Nivolumab for resected stage III or IV melanoma at 9 years. N Engl J Med. 2026;394:333\u201342.","journal-title":"N Engl J Med."},{"key":"20378_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114327","volume":"211","author":"AM Eggermont","year":"2024","unstructured":"Eggermont AM, Kicinski M, Blank CU, et al. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325\/KEYNOTE-054 trial. Eur J Cancer. 2024;211:114327.","journal-title":"Eur J Cancer."},{"key":"20378_CR12","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211\u201322.","journal-title":"N Engl J Med."},{"key":"20378_CR13","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","volume":"23","author":"GV Long","year":"2022","unstructured":"Long GV, Luke JJ, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022;23:1378\u201388.","journal-title":"Lancet Oncol."},{"key":"20378_CR14","doi-asserted-by":"publisher","first-page":"1336441","DOI":"10.3389\/fonc.2024.1336441","volume":"14","author":"AE Frey","year":"2024","unstructured":"Frey AE, Kerekes DM, Khan SA, et al. Immunotherapy utilization in stage IIIA melanoma: less may be more. Front Oncol. 2024;14:1336441.","journal-title":"Front Oncol."},{"key":"20378_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers16061197","volume":"16","author":"R Pikturniene","year":"2024","unstructured":"Pikturniene R, Cesas A, Jarmalaite S, et al. Harnessing ctDNA in advanced melanoma: a promising tool for informed clinical decisions. Cancers (Basel). 2024;16:1\u201312.","journal-title":"Cancers (Basel)."},{"key":"20378_CR16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/cncr.34716","volume":"129","author":"Z Eroglu","year":"2023","unstructured":"Eroglu Z, Krinshpun S, Kalashnikova E, et al. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer. 2023;129:1723\u201334.","journal-title":"Cancer."},{"key":"20378_CR17","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/annonc\/mdx717","volume":"29","author":"RJ Lee","year":"2018","unstructured":"Lee RJ, Gremel G, Marshall A, et al. Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma. Ann Oncol. 2018;29:490\u20136.","journal-title":"Ann Oncol."},{"key":"20378_CR18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdz048","volume":"30","author":"L Tan","year":"2019","unstructured":"Tan L, Sandhu S, Lee RJ, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 2019;30:804\u201314.","journal-title":"Ann Oncol."},{"key":"20378_CR19","doi-asserted-by":"publisher","unstructured":"Ansstas G, Khaddour K, Sudhaman S, et al. Longitudinal ctDNA monitoring for post-surgical disease surveillance in patients with stage I-IIIB melanoma. Clin Cancer Res. Published online March 10, 2026. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-3643.","DOI":"10.1158\/1078-0432.CCR-25-3643"},{"key":"20378_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813\u201323.","journal-title":"N Engl J Med."},{"key":"20378_CR21","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391:1696\u2013708.","journal-title":"N Engl J Med."},{"key":"20378_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25:454\u201361.","journal-title":"Nat Med."},{"key":"20378_CR23","doi-asserted-by":"crossref","unstructured":"Miura J, Farooq MS, Gimotty PA, et al. Neoadjuvant-adjuvant pembrolizumab in clinical stage IIB\/C melanoma. J Clin Oncol. 2025;43(suppl; abstr 9502).","DOI":"10.1200\/JCO.2025.43.16_suppl.9502"},{"key":"20378_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1245\/s10434-020-08706-0","volume":"28","author":"D Han","year":"2021","unstructured":"Han D, Han G, Duque MT, et al. Sentinel lymph node biopsy is prognostic in thickest melanoma cases and should be performed for thick melanomas. Ann Surg Oncol. 2021;28:1007\u201316.","journal-title":"Ann Surg Oncol."},{"key":"20378_CR25","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.1245\/s10434-023-14050-w","volume":"30","author":"CJ Holmberg","year":"2023","unstructured":"Holmberg CJ, Mikiver R, Isaksson K, et al. Prognostic significance of sentinel lymph node status in thick primary melanomas (>4 mm). Ann Surg Oncol. 2023;30:8026\u201333.","journal-title":"Ann Surg Oncol."},{"key":"20378_CR26","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1200\/JCO.19.02362","volume":"38","author":"SN Lo","year":"2020","unstructured":"Lo SN, Ma J, Scolyer RA, et al. Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the Melanoma Institute Australia Nomogram. J Clin Oncol. 2020;38:2719\u201327.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20378-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20378-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20378-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:50:08Z","timestamp":1792443008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20378-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":26,"alternative-id":["20378"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20378-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BP Doonan\u2013Clinical research funding from Merck for clinical trial unrelated to adjuvant use. M Seetharam\u2013Advisory board: Daiichi Sankyo and Immunocore. RS Dronca\u2013Funded investigator-initiated trial with BMS. Advisory board: BMS, Replimune, Immunocore.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}